|
|
||||||||
From the Department of Neurology, University of Texas Medical School, Houston, Texas.
Address correspondence and reprint requests to Dr. Lewis B. Morgenstern, Department of Neurology, University of Texas Medical School, 6431 Fannin 7.044, Houston TX 77030. Email: Lewis.Morgenstern{at}uth.tmc.edu
Although no neuroprotective agent is yet available for acute stroke patients, the information we have gleaned from clinical neuroprotective trials is incredibly valuable. We know that these agents are biologically active, potentially safe, and likely to have a primary role in the acute treatment of the stroke patient. The ischemic cascade has been attacked from a myriad of directions, and we now appreciate some of the advantages and limitations of preclinical models. We can use this knowledge to design more effective trials in the future.
This article has been cited by other articles:
![]() |
Y.-J. Liu, C.-Y. Chen, H.-W. Chung, I.-J. Huang, C.-S. Lee, S.-C. Chin, and M. Liou Neuronal Damage after Ischemic Injury in the Middle Cerebral Arterial Territory: Deep Watershed versus Territorial Infarction at MR Perfusion and Spectroscopic Imaging Radiology, November 1, 2003; 229(2): 366 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Tirschwell, W.T. Longstreth Jr, K. J. Becker, R. E. Gammans Sr, L. A. Sabounjian, S. Hamilton, and L. B. Morgenstern Shortening the NIH Stroke Scale for Use in the Prehospital Setting Stroke, December 1, 2002; 33(12): 2801 - 2806. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Gladstone, S. E. Black, and A. M. Hakim Toward Wisdom From Failure: Lessons From Neuroprotective Stroke Trials and New Therapeutic Directions Stroke, August 1, 2002; 33(8): 2123 - 2136. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |